ABBV Latest Press Releases

-- October 23, 2026 --

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease PRNewswire 3:35 PM

-- October 22, 2026 --

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa PRNewswire 9:00 AM

-- October 21, 2026 --

Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa Evidence PRNewswire 8:01 AM

AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE in Platinum-Resistant Ovarian Cancer PRNewswire 7:04 AM

-- October 20, 2026 --

Health Canada Approves SKYRIZI (risankizumab) for Children Living with Moderate to Severe Plaque Psoriasis PRNewswire 8:02 AM

AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community PRNewswire 7:56 AM

-- October 19, 2026 --

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-a47 Monotherapy in Moderate to Severe Crohn's Disease PRNewswire 4:01 AM

-- October 18, 2026 --

/C O R R E C T I O N - AbbVie/ PRNewswire 9:19 PM

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio PRNewswire 6:11 PM

-- October 17, 2026 --

SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 PRNewswire 2:01 AM

-- October 13, 2026 --

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease PRNewswire 3:15 PM

-- October 11, 2026 --

New SKYRIZI (risankizumab-rzaa) and RINVOQ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease PRNewswire 1:01 PM

-- October 7, 2026 --

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC PRNewswire 8:30 AM

-- October 5, 2026 --

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma PRNewswire 2:55 PM

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Business Wire 2:50 PM

-- October 1, 2026 --

AbbVie Presents Long-Term RINVOQ (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo PRNewswire 10:02 AM

AbbVie to Host Third-Quarter 2026 Earnings Conference Call PRNewswire 8:01 AM

-- September 30, 2026 --

AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 PRNewswire 5:45 AM

AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 PRNewswire 1:30 AM

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress PRNewswire 1:00 AM

-- September 29, 2026 --

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development PRNewswire 9:01 AM

-- September 28, 2026 --

U.S. FDA Approves AbbVie's JUVMO (tavapadon) for Parkinson's Disease PRNewswire 8:01 AM

-- September 24, 2026 --

EPKINLY receives Health Canada Approval for Adults with Follicular Lymphoma PRNewswire 7:01 AM

-- September 22, 2026 --

Allergan Aesthetics Debuts AA Signature in the United States with SKIN360, Its First Multimodal Consultation Approach PRNewswire 8:01 AM

AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis PRNewswire 2:00 AM

-- September 21, 2026 --

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery PRNewswire 8:00 AM

-- September 18, 2026 --

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR (cariprazine) at Psych Congress 2026 PRNewswire 8:30 AM

-- September 17, 2026 --

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting PRNewswire 8:30 AM

Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications PRNewswire 8:00 AM

-- September 15, 2026 --

AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum PRNewswire 9:01 AM

AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign PRNewswire 8:32 AM

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit PRNewswire 8:00 AM

-- September 10, 2026 --

AbbVie Declares Quarterly Dividend PRNewswire 2:19 PM

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine PRNewswire 8:56 AM

-- September 3, 2026 --

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma PRNewswire 9:16 AM

AbbVie Completes Acquisition of Apogee Therapeutics PRNewswire 8:35 AM

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference PRNewswire 8:05 AM

-- September 2, 2026 --

Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care PRNewswire 8:01 AM

-- September 1, 2026 --

SkinMedica Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings PRNewswire 8:05 AM

-- August 31, 2026 --

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference PRNewswire 8:01 AM

-- August 27, 2026 --

AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease PRNewswire 2:00 AM

-- August 21, 2026 --

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline PRNewswire 7:45 AM

-- August 18, 2026 --

A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. Globe Newswire 12:57 PM

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support PRNewswire 8:00 AM

-- August 12, 2026 --

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For Globe Newswire 9:15 AM

-- August 11, 2026 --

Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today's Modern Aesthetics Practices PRNewswire 8:01 AM

-- August 4, 2026 --

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One Globe Newswire 9:05 AM

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX Cosmetic for Masseter Muscle Prominence PRNewswire 8:00 AM

UBRELVY (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment PRNewswire 6:01 AM

-- July 31, 2026 --

AbbVie Reports Second-Quarter 2026 Financial Results PRNewswire 7:48 AM

-- July 30, 2026 --

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE Business Wire 12:07 PM

JUVDERM Day Returns to U.S. on August 19 PRNewswire 8:01 AM

-- July 29, 2026 --

AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo PRNewswire 3:00 AM

AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata PRNewswire 3:00 AM

-- July 23, 2026 --

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Business Wire 4:00 PM

-- July 17, 2026 --

Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients PRNewswire 8:00 AM

-- July 14, 2026 --

SkinMedica Deepens Commitment to Regenerative Science with Continued Investment in Research and Development PRNewswire 8:05 AM

-- July 9, 2026 --

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics PRNewswire 8:17 AM

-- July 7, 2026 --

A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It PRNewswire 9:45 AM

-- July 6, 2026 --

AbbVie Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma PRNewswire 1:45 PM

-- July 1, 2026 --

A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity Globe Newswire 9:05 AM

-- June 29, 2026 --

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma PRNewswire 4:15 PM

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata PRNewswire 3:10 AM

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo PRNewswire 3:00 AM

-- June 26, 2026 --

SKYRIZI (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease PRNewswire 4:52 PM

AbbVie to Host Second-Quarter 2026 Earnings Conference Call PRNewswire 8:00 AM

-- June 25, 2026 --

The Aesthetics Giants Just Confirmed 'Ozempic Face' Is Real - and a Newly Public Regenerative Player Wants to Compete for It Globe Newswire 9:04 AM

-- June 24, 2026 --

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE Business Wire 2:25 PM

BOTOX Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 PRNewswire 8:00 AM

-- June 23, 2026 --

Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients PRNewswire 8:00 AM

AbbVie Announces European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection PRNewswire 5:01 AM

AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis PRNewswire 3:00 AM

-- June 22, 2026 --

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio PRNewswire 7:00 AM

-- June 18, 2026 --

AbbVie Declares Quarterly Dividend PRNewswire 4:06 PM

-- June 16, 2026 --

Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower PRNewswire 8:15 AM

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVDERM for the Improvement of Neck Appearance PRNewswire 8:00 AM

-- June 12, 2026 --

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results PRNewswire 3:00 AM

-- June 10, 2026 --

Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics PRNewswire 8:00 AM

-- June 8, 2026 --

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 PRNewswire 8:00 AM

-- June 2, 2026 --

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference PRNewswire 8:00 AM

-- May 29, 2026 --

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia PRNewswire 8:00 AM

-- May 27, 2026 --

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options PRNewswire 6:18 PM